Replies to post #163205 on Biotech Values

[DewDiligence]

GILD—Sofo/Ledipasvir (5885) went 9/9 in a small study of nulls.

In GILD’s Jan 2013 PR (#msg-83134184), the 9/9 result you’re referring to was an SVR4 rate. Has GILD reported SVR12 or SVR24 for this cohort?